AU769847C - Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application - Google Patents

Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application

Info

Publication number
AU769847C
AU769847C AU27034/00A AU2703400A AU769847C AU 769847 C AU769847 C AU 769847C AU 27034/00 A AU27034/00 A AU 27034/00A AU 2703400 A AU2703400 A AU 2703400A AU 769847 C AU769847 C AU 769847C
Authority
AU
Australia
Prior art keywords
asp
ala
tetrapeptide
glu
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU27034/00A
Other languages
English (en)
Other versions
AU769847B2 (en
AU2703400A (en
Inventor
Vladimir Khatskelevich Khavinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIJU "KLINIKA INSTITUTA BIOREGULYATSII I GERONTOLOGII"
Original Assignee
OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIJU "KLINIKA INSTITUTA BIOREGULYATSII I GERONTOLOGII"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIJU "KLINIKA INSTITUTA BIOREGULYATSII I GERONTOLOGII" filed Critical OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIJU "KLINIKA INSTITUTA BIOREGULYATSII I GERONTOLOGII"
Publication of AU2703400A publication Critical patent/AU2703400A/en
Publication of AU769847B2 publication Critical patent/AU769847B2/en
Application granted granted Critical
Publication of AU769847C publication Critical patent/AU769847C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU27034/00A 1999-05-11 2000-01-20 Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application Ceased AU769847C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU99108841/14A RU2157233C1 (ru) 1999-05-11 1999-05-11 Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения
RO99108841 1999-05-11
PCT/RU2000/000012 WO2000068255A2 (en) 1999-05-11 2000-01-20 Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application

Publications (3)

Publication Number Publication Date
AU2703400A AU2703400A (en) 2000-11-21
AU769847B2 AU769847B2 (en) 2004-02-05
AU769847C true AU769847C (en) 2005-02-17

Family

ID=20219149

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27034/00A Ceased AU769847C (en) 1999-05-11 2000-01-20 Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application

Country Status (11)

Country Link
US (1) US6727227B1 (enExample)
EP (1) EP1179008B1 (enExample)
JP (1) JP3902406B2 (enExample)
AT (1) ATE321068T1 (enExample)
AU (1) AU769847C (enExample)
CA (1) CA2373128C (enExample)
DE (1) DE60026826T2 (enExample)
ES (1) ES2259998T3 (enExample)
IL (2) IL146432A0 (enExample)
RU (1) RU2157233C1 (enExample)
WO (1) WO2000068255A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
EP1138692A1 (en) * 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
EP1300418A1 (en) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7576174B2 (en) * 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
RU2161501C1 (ru) * 2000-06-29 2001-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Способ получения пептидов, обладающих тканеспецифической активностью, и фармацевтические композиции на их основе
WO2002090380A1 (en) * 2001-04-17 2002-11-14 Sankt-Peterburgskaya Obschestvennaya Organizatsiya 'institut Bioregulyatsii I Gerontologii Czo Ramn' Tetrapeptide stimulating the retinal function and the method of its application
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
RU2257910C1 (ru) * 2003-12-25 2005-08-10 Институт физиологически активных веществ Российской Академии Наук (ИФАВ РАН) Растительные экстракты, обладающие геропротекторной активностью и средство на их основе
RU2257909C1 (ru) * 2003-12-25 2005-08-10 Институт физиологически активных веществ Российской Академии Наук (ИФАВ РАН) Концентрат побегов черники и композиции на его основе, обладающие геропротекторной активностью
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
RU2255757C1 (ru) * 2004-06-22 2005-07-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Пептидное соединение, восстанавливающее функцию органов дыхания
RU2255756C1 (ru) * 2004-06-22 2005-07-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Пептидное соединение, восстанавливающее функцию миокарда
RU2297215C2 (ru) * 2005-02-21 2007-04-20 Государственное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет им. акад. И.П. Павлова" МЗ РФ Антиоксидантное средство для лечения катаракты
WO2007004869A2 (en) * 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
RU2295970C1 (ru) * 2006-05-23 2007-03-27 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Пептид, повышающий резистентность капилляров, фармацевтическая композиция на его основе и способ ее применения
RU2304444C1 (ru) * 2006-05-23 2007-08-20 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Пептид, обладающий стресспротекторным действием, фармацевтическая композиция на его основе и способ ее применения
RU2301074C1 (ru) * 2006-05-30 2007-06-20 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Пептид, обладающий иммуногеропротекторным действием, фармацевтическая композиция на его основе и способ ее применения
RU2301678C1 (ru) 2006-05-30 2007-06-27 Общество С Ограниченной Ответственностью "Сиа Пептайдс" Пептид, стимулирующий регенерацию нейронов центральной нервной системы, фармацевтическая композиция на его основе и способ ее применения
PT2120991E (pt) * 2007-02-12 2014-05-02 Biotempt Bv Tratamento d a hemorragia traumática com oligopéptidos curtos
RU2464816C1 (ru) * 2011-04-14 2012-10-27 Общество с ограниченной ответственностью "Вилави" Композиция биологически активных веществ, обладающая геропротекторной активностью, и способ комплексной коррекции возрастных изменений гормонального баланса, функций эпифиза и антиоксидантного статуса, включающий введение указанной композиции
MY190600A (en) * 2015-05-22 2022-04-27 A2 Milk Co Ltd Beta-casein a2 and antioxidant capacity
CA3175267A1 (en) * 2020-04-15 2021-10-21 Anton MALYSHEV Synthetic peptides for modulating the metabotropic glutamate receptor 5
KR102841388B1 (ko) * 2022-08-30 2025-08-01 주식회사 제이포셀 항노화 펩타이드 및 황기 추출물을 포함하는 항노화 화장료 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH078273A (ja) * 1993-06-14 1995-01-13 Kurabo Ind Ltd 接着性動物細胞の無血清培養法
JPH0851980A (ja) * 1994-08-11 1996-02-27 Asahi Glass Co Ltd 合成遺伝子およびこれを用いた癌転移阻害活性を有するペプチドの製造方法
RU2099078C1 (ru) * 1994-12-08 1997-12-20 Акционерное общество закрытого типа "КОМКОН" Средство, обладающее антистрессовым, стресспротекторным, ноотропным, антиалкогольным и антинаркотическим действием, способы профилактики и лечения с его использованием
RU2112512C1 (ru) * 1995-09-22 1998-06-10 Иванов Евгений Васильевич Биологичеcки активная пищевая добавка "глутапирон", обладающая антиканцерогенным и геропротекторным действием
DE19882746T1 (de) * 1997-04-03 2001-10-18 California Inst Of Techn Enzymvermittelte Modifikation von Fibrin für das Gewebs-Engineering

Also Published As

Publication number Publication date
AU769847B2 (en) 2004-02-05
IL146432A0 (en) 2002-07-25
DE60026826T2 (de) 2007-04-12
IL146432A (en) 2007-06-03
JP3902406B2 (ja) 2007-04-04
WO2000068255A2 (en) 2000-11-16
EP1179008A2 (en) 2002-02-13
ATE321068T1 (de) 2006-04-15
WO2000068255A3 (en) 2001-06-14
JP2003526622A (ja) 2003-09-09
CA2373128A1 (en) 2000-11-16
EP1179008B1 (en) 2006-03-22
ES2259998T3 (es) 2006-11-01
US6727227B1 (en) 2004-04-27
RU2157233C1 (ru) 2000-10-10
AU2703400A (en) 2000-11-21
CA2373128C (en) 2007-03-13
DE60026826D1 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
AU769847C (en) Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application
EP0309100B1 (en) Use of amylin or CGRP for the treatment of diabetes mellitus
US9308192B2 (en) Use of NRF2 inducers to treat epidermolysis bullosa simplex and related diseases
KR100248030B1 (ko) 시토킨 조절제 및 시토킨 농도 변화에 관련된 병변 및 질환에 있어서 그의 용도
HK1000934B (en) Use of amylin or cgrp for the treatment of diabetes mellitus
US5175145A (en) Treatment of diabetes mellitus with amylin agonists
US10835573B2 (en) Methods for treating Friedreich's ataxia by an aromatic-cationic peptide to increase frataxin protein levels
US20100105864A1 (en) Prophylactic or therapeutic agent for diarrhea
CN103751763A (zh) 用于预防或治疗血管阻塞损伤的方法
CA2230968A1 (en) Method of treating insulin resistance
CN109152810A (zh) 用于预防和治疗杜氏肌肉萎缩症的方法和组合物
JP2013545809A (ja) 骨格筋および皮膚の成長、修復、および維持を促進するようにブラシノステロイドを産生および使用する方法
HU226567B1 (en) Use of phenylhydrazon derivates for the preparation of medicaments for the inhibition of neurogenic and non-neurogenic inflammations and for the alleviation of pain
TAMAI et al. Prolongation of life span of dystrophic hamster by cysteine proteinase inhibitor, loxistatin (EST)
EP2482833A1 (en) Leptin agonist and methods of use
WO2007002469A2 (en) Therapeutic compositions and methods using transforming growth factor-beta mimics
WO2019143192A1 (ko) 듀니온을 유효성분으로 포함하는 탈모의 예방 또는 개선용 조성물
RU2242241C1 (ru) Тетрапептид, регулирующий уровень глюкозы при сахарном диабете, фармакологическое средство на его основе и способ его применения
ES2302067T3 (es) Sustancia peptidica que restaura la funcion del miocardio.
EP1353939B1 (en) Tetrapeptide regulating prostate functions and its compositions and uses
Riley et al. Effect of proline analogs on oxygen toxicity-induced pulmonary fibrosis in the rat
RU2768475C1 (ru) Пептид, обладающий нейростимулирующей активностью и восстанавливающий способность к обучению и формированию памяти, фармацевтическая композиция на его основе и способ ее применения
RU2763761C1 (ru) Гепатопротекторное гуминовое средство
HK1001621A (en) Amylin isolated from pancreatic islet amyloid and pharmaceutical compositions comprising it

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20040519